Key Highlights
● Eli Lilly closed at an all-time high of $1,373.70 after a big third-quarter beat.
● Lilly raised 2026 Revenue guidance to $91 billion to $92 billion.
● Merck beat estimates, raised its profit outlook and led the Dow's gainers.
● Gilead and DexCom rose after hours while Stryker fell sharply.
Drugmakers took control of the tape on Thursday, as Blowout results from Eli Lilly (NYSE:LLY) and a beat-and-raise from Merck (NYSE:MRK) made health care the S&P 500's best sector.
The leader of the pack
While Alphabet (NASDAQ:GOOGL)'s collapse dominated the headlines, health care quietly led the market. It was the S&P 500's best-performing sector on Thursday, according to market data, ahead of real estate, consumer staples and utilities. At midday, the Health Care Select Sector SPDR, XLV, was climbing and the pharmaceutical ETF IHE was rising even faster, according to market data.
One source said investors rotated into health care, financials and real estate, which helped limit losses in the broader indexes.
Lilly's record day
Eli Lilly was the biggest driver. The drugmaker closed at $1,373.70, an all-time high, according to media reports. Its third-quarter numbers cleared Wall Street's bar with room to spare.
Revenue reached $24.40 billion, well above the $22.61 billion analysts expected, and adjusted Earnings of $7.48 a share crushed the $6.26 estimate, according to market data. Market commentary said Demand was led by its weight-loss and diabetes drugs Zepbound and Mounjaro.
Lilly raised its 2026 revenue guidance to $91 billion to $92 billion, up from $85 billion to $87 billion. It trimmed its adjusted earnings guidance to $35 to $36 a share from $35.50 to $36.50 because of $4.57 a share in acquired research charges. One soft spot: sales of Foundayo missed, according to market data.
Merck leads the Dow
Merck also delivered. The company beat on revenue and adjusted earnings and raised its full-year profit outlook despite absorbing licensing charges, according to market commentary. Its cancer drug Keytruda, including a subcutaneous version, and its pulmonary hypertension drug Winrevair, whose sales nearly doubled from a year earlier, drove the results. One headline said Merck led the Dow's gainers.
Beyond the big two
The rally spread across health care. HCA Healthcare (NYSE:HCA) rose after beating on revenue and earnings and saying it expects to land in the upper half of its guidance ranges, according to market commentary. Bristol Myers Squibb (NYSE:BMY) edged higher after raising its 2026 revenue guidance to $49.75 billion to $50.25 billion. Insmed (NASDAQ:INSM) jumped after revenue of $524.4 million beat estimates on strong sales of Brinsupri.
Among smaller names, Glaukos (NYSE:GKOS) soared on record net sales of $211.0 million and raised guidance, while Teladoc Health (NYSE:TDOC) rallied after its revenue and profitability beat forecasts.
Not everything rose. Alnylam Pharmaceuticals (NASDAQ:ALNY) tumbled after warning that sales of a key Franchise would likely land at the low end of guidance. CEO Yvonne Greenstreet said the company is "not yet satisfied with the underlying demand growth we have observed."
The rotation in context
Health care's strength came as investors pulled money from AI-exposed technology. Alphabet suffered its worst day since its 2004 IPO, and the Nasdaq Composite fell 365.13 points to 26,184.72. The S&P 500 slipped 23.59 points to 7,720.39, but more than 400 of its members rose, and the Russell 2000 gained 28.71 points to 2,859.22.
One strategist captured the mood: "There's plenty of other places to go with your money outside of the AI trade that have pretty decent prospects."
What to watch
Health care's earnings run continues. After Thursday's close, Gilead Sciences (NASDAQ:GILD) edged higher in extended trading after raising its base-business guidance for the third time this year, and DexCom (NASDAQ:DXCM) rose after beating estimates. Stryker (NYSE:SYK), by contrast, fell sharply after hours after missing on revenue and guiding below consensus.
AbbVie (NYSE:ABBV) reports on Friday, offering another read on big pharma. For Lilly, investors will watch whether demand for Zepbound and Mounjaro keeps outrunning forecasts. If the rotation away from megacap tech persists, health care will be one of the first places to see whether the money stays.






Please wait processing your request...